Midodrine Teva (Midodrine Hydrochloride)

Midodrine is converted in the body to desglymidodrine, which selectively activates α1‑adrenergic receptors on peripheral blood vessels. This activation causes vasoconstriction, increasing systemic vascular resistance and elevating arterial pressure, especially when a patient moves to an upright position.

The prescribed dose of Midodrine is individualized by the treating clinician based on the patient’s blood‑pressure response and tolerance. Typical regimens start with a low dose taken several times daily, but the exact amount and schedule must be determined by a qualified healthcare professional.

Safety data for Midodrine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Midodrine differs from agents such as fludrocortisone by directly causing peripheral vasoconstriction rather than expanding plasma volume. It often provides a faster rise in standing blood pressure, whereas fludrocortisone works more gradually through sodium retention. Choice of therapy depends on patient profile, comorbidities and physician judgment.

Midodrine Teva tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct light, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Midodrine Teva is taken orally, usually with a full glass of water. Doses are generally spaced throughout the day, and the medication should be taken during waking hours to avoid supine hypertension. Patients should follow the prescribing clinician’s instructions regarding timing and food intake.

The most critical safety concerns include severe or supine hypertension, which can lead to chest pain, stroke, or organ damage, and rare cardiac arrhythmias such as bradycardia. Patients should report any sudden headache, visual changes, chest discomfort, or palpitations promptly to their healthcare provider.

Midodrine is contraindicated in patients with severe organic heart disease, uncontrolled hypertension, or known hypersensitivity to the drug or its excipients. It should also be avoided in individuals with urinary retention due to prostate enlargement unless closely monitored, and in anyone where the risk‑benefit assessment is unfavorable.